Prabotulinumtoxin A biosimilar by AEON Biopharma for Migraine: Likelihood of Approval

Prabotulinumtoxin A biosimilar is under clinical development by AEON Biopharma and currently in Phase II for Migraine.

At a flashy new research hub, AstraZeneca lays out ambitious growth goals

CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious growth goals for the rest of the decade, seeking to

May 21, 2024

Consolidated interim results as per June 30th,2023 – Biotech Investments

EQS-News: Vitruvia Medical AG / Key word(s): Half Year Results/Half Year Report Vitruvia Medical AG: Consolidated interim results as per June 30th,2023 29.09.2023 / 13:15

September 30, 2023

Americans Struggling With Addiction, Mental Health, SAMHSA Survey Shows

The Substance Abuse and Mental Health Services Administration (SAMHSA) released the results of its 2022 National Survey on Drug Use and Health (NSDUH) on Tuesday,

November 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.